Notice of Correction  by unknown
community interests. For instance, in the se-
ries reported by Webb and colleagues,4 72%
had coronary artery disease. No data de-
scribe how these patients have been man-
aged. Furthermore, a long series of
exclusion criteria precluded the percutane-
ous aortic valve implantation in this and
other series,3,4 although the implantation
of a percutaneous prosthesis is initially con-
sidered in patients with absolute surgical
contraindications. Nevertheless, in the expe-
rience reported by Webb and associates,4
a patient had been successfully converted
to surgery. By using epidural anesthesia,
my colleagues and I2 did not add any cost,
and we greatly reduced the need for inten-
sive care unit management. On the other
hand, considering that the percutaneous
prostheses are sold at a cost 10-fold higher
than a standard bioprostheses, and consider-
ing the early 30-day results of percutaneous
implantation,1,3,4 we maintain that surgery
at the moment is to be preferred over a percu-
taneous approach. On the contrary, we be-
lieve that currently there are no factors that
might preclude surgery for any patient. In-
stead of finding a way to replace surgical
therapy, percutaneous approaches should
be used as an adjunct to surgery, to support
it in its current limitations, such as being
used to replace deteriorating bioprostheses
and avoiding the complications related to
repeated heart dissections.5
Tomaso Bottio, MD, PhD
Cardiovascular Institute
University of Padua Medical School
Padua, Italy
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